23 results
8-K
EX-99.1
ALLK
Allakos Inc
16 Jan 24
Regulation FD Disclosure
6:17pm
, manufacturing, research and administrative functions Reduce our workforce by almost 50% The Company anticipates that the significant majority
8-K
ALLK
Allakos Inc
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
, manufacturing, research and administrative functions. The Company also committed to reducing its workforce by approximately 50%.
The total costs … related to halting lirentelimab-related activities and reducing the workforce are estimated to be approximately $30 million, with the majority
8-K
EX-99.1
ALLK
Allakos Inc
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
and administrative functions. As a result, the Company will reduce its workforce by approximately 50%.
Cash Guidance
The Company ended the fourth
8-K
EX-99.1
5lzd7v1 wvaka2
6 May 22
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K/A
EX-99.1
937m0qn1rcqkjardeb
15 Feb 22
Other Events
10:02am
8-K
EX-99.1
psgb9zil vdo696pk
15 Feb 22
Other Events
8:00am